TLR4 and neoplasm: In humans, the IT delivery of the synthetic TLR4 agonist Glucopyranosyl Lipid A (G100) has showed success in early clinical trials in eliciting Th1 polarized anti-tumor immunity in Merkel cell carcinoma and soft tissue sarcoma, in combination with RT (NCT02501473) (175, 176).